Phase 1 Cytomegalovirus Clinical Trials
9 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
Congenital Cytomegalovirus Infection
National Institute of Allergy and Infectious Diseases (NIAID)12 enrolled10 locationsNCT06118515
Recruiting
Phase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Cytomegalovirus Prophylaxis
Merck Sharp & Dohme LLC40 enrolled12 locationsNCT07199465
Recruiting
Phase 1Phase 2
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Epstein-Barr Virus InfectionsCytomegalovirus InfectionsAdenovirus
Jessie L. Alexander25 enrolled3 locationsNCT06909110
Recruiting
Phase 1
R-MVST Cells for Treatment of Viral Infections
Epstein-Barr Virus InfectionsCytomegalovirus InfectionsBK Virus Infection+1 more
Columbia University36 enrolled1 locationNCT05183490
Recruiting
Phase 1
Virus-specific T cell therapy for transplant recipients
recurrent or drug-resistant viral infectionViral reactivationBK polyomavirus+1 more
QIMR Berghofer Medical Research Institute25 enrolled4 locationsACTRN12621000323820
Recruiting
Phase 1
Coadministration of Malignancy and Infection specific T cells after allogeneic stem cell Transplant for Acute Leukaemia with CD34+ selected stem cells
AspergillusInfluenza virusBK Virus+2 more
Western Sydney Local Health District, Westmead Hospital20 enrolled1 locationACTRN12618001090202
Completed
Phase 1
Infusion of virus specific immune cells in patients at the first sign of virus infection after a blood or bone marrow transplant who have received less than 7 days of anti-viral treatment.
Cytomegalovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationAdenovirus reactivation or infection following allogeneic blood or marrow stem cell transplantationEpstein Barr Virus reactivation or infection following allogeneic blood or marrow stem cell transplantation
Western Sydney Local Health District31 enrolled3 locationsACTRN12618000343202
Completed
Phase 1
This study is assessing the feasibility of generating expanded T cells for the treatment of cytomegalovirus (CMV) reactivation and disease, and the subsequent evaluation of safety.
Cytomegalovirus
QIMR Berghofer Medical Research Institute.30 enrolled3 locationsACTRN12613000981729
Recruiting
Phase 1
A phase 1 clinical trial of peptide-pulsed monocyte-derived dendritic cell vaccination to expand adoptively transferred cytomegalovirus -specific cytotoxic T lymphocytes after allogeneic stem cell transplantation
Cytomegalovirus (CMV) reactivation and disease
Western Sydney Local Health District18 enrolled1 locationACTRN12608000458336